Today: 27 June 2026
Wesfarmers share price today: WES ends higher as market waits for Feb. 19 half-year results
17 February 2026
1 min read

Wesfarmers share price today: WES ends higher as market waits for Feb. 19 half-year results

SYDNEY, Feb 17, 2026, 17:28 AEDT — Market closed

  • Wesfarmers closed Tuesday at A$88.98, up 0.3%.
  • Wesfarmers’ half-year numbers land Feb. 19, and investors are already staking out their positions.
  • Investors are zeroed in on retail demand at Bunnings and Kmart, plus any word on how second-half trading is shaping up.

Shares of Wesfarmers Ltd (WES.AX) edged 0.3% higher to A$88.98 on Tuesday. Investors seemed to brush off the day’s trading action, keeping their attention on the retailer’s upcoming half-year results later this week.

Big player in Australian retail and consumer—think Bunnings, Kmart, Officeworks—the group covers a lot of ground. A half-year update landing right on top of reporting season peak can jolt expectations quickly, even though the stock hasn’t shown much movement.

This snapshot lands as traders look for clues about the consumer heading into the back half, and wonder if markdowns are starting to take a bite out of margins. Hold steady, and the stock’s sluggish crawl probably continues. Miss on sales or guidance, though, and that changes fast.

The S&P/ASX 200 ticked up 0.24% on Tuesday, according to data. Wesfarmers saw roughly 934,000 shares move, with the stock fluctuating from A$88.15 to as high as A$89.47. JB Hi-Fi surged over 8%, a reminder of just how sharply retail stocks can react to earnings.

Wesfarmers shares have added roughly 3.2% in the last week and edged up another 0.3% from Tuesday’s open, market data from Intelligent Investor show.

Wesfarmers faces the usual set of questions: what’s happening with Bunnings’ trade demand, whether Kmart’s managing to keep prices and volumes steady, and if Officeworks is finally finding its footing after some turbulence in discretionary spending. Costs are still in focus — shifts in wages, freight, or rent can rewrite the narrative, regardless of what’s showing up in the sales numbers.

Sheldon Renkema, executive general manager, told the Australian Securities Exchange in a Jan. 19 notice that half-year results are set for release on Thursday, 19 February 2026. The analyst call’s scheduled for 10:00 a.m. AWST, or 1:00 p.m. AEDT.

Dividend chatter is likely to linger around the result. Investors usually zero in on cash generation, capital allocation, and just how fast management is putting money back into the portfolio—details that can all sway how the market values what comes next for shareholders.

But there’s risk here, too. If competition ramps up, promotions get steeper, or management strikes a cautious note about the back half, shares could easily slip from the A$90 zone—especially after the latest rally.

Looking ahead, the next notable mover is Thursday—Wesfarmers drops its half-year report and holds a briefing, both flagged on its results and presentations page. The webcast link for the event is already live.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Nvidia Invests in AI-Driven Biotechnology Firm Generate Biomedicines, Targeting $1.8 Trillion Pharma Market
    June 27, 2026, 9:17 AM EDT. Nvidia (NASDAQ: NVDA) has acquired 833,325 shares in Generate Biomedicines (NASDAQ: GENB), a $2 billion market cap biotechnology company using AI to digitally test drug molecules. This minority stake reflects Nvidia's confidence in GENB's AI platform, which accelerates drug discovery by simulating molecule performance before costly clinical trials. Generate's pipeline includes four drug candidates, with one in phase 3 testing for severe asthma. Nvidia's venture capital arm NVentures' $13 million investment aligns with the tech giant's expertise in AI hardware, highlighting the growing convergence of AI and biopharma. The move positions Generate Biomedicines to potentially disrupt the $1.8 trillion pharmaceutical market by reducing drug development time and costs, addressing key industry challenges.

Latest articles

Oil Prices Today: Brent Whipsaws as Iran Peace Hopes Hit OPEC Supply Shock

Funds trim WTI longs, Hormuz supply flows ease squeeze from tight U.S. stocks

27 June 2026
Brent crude plunged 10.86% this week to $71.99 as funds slashed net long WTI positions by 13,356 contracts, despite Cushing inventories hitting their lowest since 2014 and U.S. diesel margins surging; investors face key risks from Hormuz traffic, U.S.-Iran tensions, OPEC+ output hikes, and China’s fuel export boost.
AI stocks eye $41 billion tech-fund shift as memory costs hit

AI stocks eye $41 billion tech-fund shift as memory costs hit

27 June 2026
Technology sector funds saw nearly $20 billion in outflows the week to June 24—erasing the prior week’s $21.46 billion inflows—just before chip stocks plunged, with the Nasdaq dropping 4.6% and the Philadelphia semiconductor index posting its worst week since April, as investors questioned AI profitability and shifted away from tech.
IPO calendar eyes Bending Spoons as shortened week thins deal pipeline

IPO calendar eyes Bending Spoons as shortened week thins deal pipeline

27 June 2026
Bending Spoons (NASDAQ:BSP) drives 61% of next week’s $2.56 billion U.S. IPO proceeds, making its $1.57 billion raise a key test for investor appetite in debt-heavy software M&A, with a $18.1 billion valuation and 4.0x net debt to EBITDA leverage, as markets brace for a holiday-shortened week and a looming $29.4 billion SK hynix Nasdaq ADR.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines
Next Story

GE stock price rises as Morgan Stanley starts GE Aerospace; American Airlines keeps CFM LEAP engines

Go toTop